Clinical Data Presented at ACC 2025 Shows Sensydia CPS™ Provides Accurate Assessment of Mean Pulmonary Artery Pressure Non-Invasively
Sensydia, a clinical-stage non-invasive cardiac assessment company, announced today that University of Minnesota investigators presented positive clinical findings from a recent study evaluating the ...
Verywell Health on MSN2d
7 Common Causes of Pulmonary Arterial Hypertension
Medically reviewed by Christopher Lee, MD Pulmonary arterial hypertension (PAH) is a type of pulmonary hypertension that ...
Pulmonary Hypertension News4d
Main pulmonary artery parameters predict PAH outcomes, study finds
A larger diameter of the main pulmonary artery predicts poorer outcomes in pulmonary arterial hypertension (PAH) patients, a ...
Houston Chronicle11d
After 2 heart surgeries, jiu-jitsu gave him strength. Then his son was diagnosed.
Testing showed Chris had a rare, life-threatening heart defect: His aorta and his pulmonary artery were switched. The aorta ...
The American Journal of Managed Care12d
Managing Pulmonary Hypertension in Pregnancy
Pulmonary arterial hypertension (PAH) can be a challenging complication to manage during pregnancy; women with PAH who are ...
The American Journal of Managed Care9d
Pulmonary Hypertension Subtypes Show Distinct PA Flow Hemodynamics
Investigators used 4D flow cardiovascular magnetic resonance imaging to search for differences between pulmonary artery (PA) ...
2 Minute Medicine5d
Merck’s Winrevair: Pulmonary arterial hypertension drug shows success ahead of schedule
Strong positive interim data from an earlier Phase 3 trial has led to early cessation of Merck’s pulmonary arterial ...
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder
Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Food and Drug ...